vidarabine has been researched along with epirubicin in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bergmann, L; Hoelzer, D; Jäger, E; Käfer, G; Mitrou, PS; Pfreundschuh, M; Reinhardt, U; Rummel, MJ | 1 |
| Algeri, R; Bigazzi, C; Bocchia, M; Forconi, F; Lauria, F; Marconcini, S; Marotta, G | 1 |
| Bosanquet, AG; Bosanquet, MI | 1 |
| Bergmann, M; Busch, R; Emmerich, B; Franke, A; Hallek, M; Hiddemann, W; Hopfinger, G; Pasold, R; Schlag, R; Schmitt, B; Wendtner, CM | 1 |
| Culligan, DJ; Johnston, PW; Milner, BJ; Mittal, S | 1 |
| Bergmann, L; Chow, KU; Cordes, HJ; Kim, SZ; Schlegelberger, B; Stilgenbauer, S; von Neuhoff, N; Wunderle, L | 1 |
| Andronescu, E; Geanaliu-Nicolae, RE; Iordache, F; Pîrvan, AA; Voicu, G | 1 |
1 review(s) available for vidarabine and epirubicin
| Article | Year |
|---|---|
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chlorambucil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2002 |
2 trial(s) available for vidarabine and epirubicin
| Article | Year |
|---|---|
Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Rate; Vidarabine | 1999 |
Clinical efficacy of immunochemotherapy with fludarabine, epirubicin and rituximab in the treatment for chronic lymphocytic leukaemia and prolymphocytic leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Male; Middle Aged; Prospective Studies; Rituximab; Vidarabine | 2011 |
7 other study(ies) available for vidarabine and epirubicin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine | 1999 |
Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Cladribine; Comorbidity; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pentostatin; Prednisolone; Prognosis; Staining and Labeling; Tumor Cells, Cultured; Vidarabine; Vincristine | 2000 |
A case of hepatosplenic gamma-delta T-cell lymphoma with a transient response to fludarabine and alemtuzumab.
Topics: Adolescent; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Crohn Disease; Cytarabine; Epirubicin; Epstein-Barr Virus Infections; Etoposide; Fatal Outcome; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunosuppressive Agents; Liver; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Male; Methylprednisolone; Pentostatin; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Spleen; Transplantation, Homologous; Vidarabine | 2006 |
Synthesis, characterization and bioevaluation of drug-collagen hybrid materials for biomedical applications.
Topics: Collagen Type I; Drug Delivery Systems; Epirubicin; Humans; Materials Testing; Pharmaceutical Preparations; Vidarabine | 2016 |